Essays

Aurobindo Pharma Ltd has announced that it has received final approval from the US PDA to manufacture and market alprazolam extended-release tablets in the quantities of 0.5 mg, 1 ing, 2 nig and 3 mg.

Alprazolam extended release tablets that would be manufactured and marketed by Aurobindo pharma is the generic equivalent to the reference listed drug Xanax® XR Tablets 0.5 mg, 1 mg, 2 mg and 3mg of Pharmacia and Upjohn. These tablets are used for the treatment of panic disorder, with 01 without agoraphobia and fall under the Central Nervous System (CNS) therapeutic segment. The product has a market size of approximately $26.5 million for the twelve months ending September 2010 according to IMS and will be launched soon.